Skip to main content
Erschienen in: Archives of Gynecology and Obstetrics 4/2013

01.04.2013 | Maternal-Fetal Medicine

Tranexamic acid for cesarean section: a double-blind, placebo-controlled, randomized clinical trial

verfasst von: Mehmet B. Sentürk, Yusuf Cakmak, Gazi Yildiz, Pınar Yildiz

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To assess the efficacy and safety of an intravenous formulation of tranexamic acid to reduce intrapartum and postpartum bleeding in patients giving birth by cesarean section.

Methods

Healthy women with normal pregnancies, at any gestational age, that we performed ceaserean section. Two hundred and twenty-three patients with cesarean section, were enrolled in a double-blind, placebo-controlled study. Tranexamic acid of 20 cc and a 20 cc 5 % dextrose solution was intravenously injected to the patients; both the study group (n = 101) and the control group (n = 122) 10 min before the start of cesarean section. We measured volume of blood loss in postoperative periods, decrease in hemoglobin and hematocrit levels after cesarean section. The mean follow up was 2 weeks after the operation.

Results

Tranexamic acid reduced intraoperative and postoperative blood loss. We did not observe any complications caused by TA such as venous thromboembolism, gastrointestinal problems and hypersensitivity.

Conclusions

This study confirms that tranexamic acid is effective in reducing intrapartum and postpartum bleeding in patients giving birth by cesarean section. Although some obstetricians are still worried about its thrombosis risk, our study shows that it can be used safely in aforementioned patients.
Literatur
1.
Zurück zum Zitat Gungorduk K, Yıldırım G (2011) Efficacy of Intravenous Tranexamic acid in reducing blood loss after elective caesarean section: a prospective, randomized, double-blindplacebo-Controlled Study. Am J Perinatol 28(3):233–240PubMedCrossRef Gungorduk K, Yıldırım G (2011) Efficacy of Intravenous Tranexamic acid in reducing blood loss after elective caesarean section: a prospective, randomized, double-blindplacebo-Controlled Study. Am J Perinatol 28(3):233–240PubMedCrossRef
2.
Zurück zum Zitat Magann EF, Evans S, Hutchinson M, Collins R, Lanneau G, Morrison JC (2005) Postpartum hemorrhage after caesarean delivery: an analysis of risk factors. South Med J 98(7):681–685PubMedCrossRef Magann EF, Evans S, Hutchinson M, Collins R, Lanneau G, Morrison JC (2005) Postpartum hemorrhage after caesarean delivery: an analysis of risk factors. South Med J 98(7):681–685PubMedCrossRef
3.
Zurück zum Zitat Hogan MC, Foreman KJ, Naghavi M, Ahn SY, Wang M, Makela SM, Lopez AD, Lozano R, Murray CJ (2010) Maternal mortality for 181 countries, 1980–2008: a systematic analysis of progress towards millennium development goal 5. Lancet 375(9726):1609–1623PubMedCrossRef Hogan MC, Foreman KJ, Naghavi M, Ahn SY, Wang M, Makela SM, Lopez AD, Lozano R, Murray CJ (2010) Maternal mortality for 181 countries, 1980–2008: a systematic analysis of progress towards millennium development goal 5. Lancet 375(9726):1609–1623PubMedCrossRef
4.
Zurück zum Zitat Ronsmans C, Graham WJ (2006) Maternal mortality: who, when, where, and why. Lancet 368(9542):1189–1200PubMedCrossRef Ronsmans C, Graham WJ (2006) Maternal mortality: who, when, where, and why. Lancet 368(9542):1189–1200PubMedCrossRef
5.
6.
Zurück zum Zitat Munn MB, Owen J, Vincent R, Wakefield M, Chestnut DH, Hauth JC (2001) Comparison of two oxytocin regimens to prevent uterine atony at caesarean delivery: a randomized controlled trial. Obstet Gynecol 98(3):386–390PubMedCrossRef Munn MB, Owen J, Vincent R, Wakefield M, Chestnut DH, Hauth JC (2001) Comparison of two oxytocin regimens to prevent uterine atony at caesarean delivery: a randomized controlled trial. Obstet Gynecol 98(3):386–390PubMedCrossRef
7.
Zurück zum Zitat Sekhavat L, Tabatabaii A, Dalili M, Farajkhoda T, Tafti AD (2009) Efficacy of tranexamic acid in reducing blood loss after caesarean section. J Matern Fetal Neonatal Med 22(1):72–75PubMedCrossRef Sekhavat L, Tabatabaii A, Dalili M, Farajkhoda T, Tafti AD (2009) Efficacy of tranexamic acid in reducing blood loss after caesarean section. J Matern Fetal Neonatal Med 22(1):72–75PubMedCrossRef
8.
Zurück zum Zitat Shakur H, Elbourne D, Gülmezoglu M, Alfirevic Z, Ronsmans C, Allen E, Roberts I (2010) The WOMAN Trial (World Maternal Antifibrinolytic Trial): tranexamic acid for the treatment of postpartum haemorrhage: an international randomised, double blind placebo controlled trial. Trials 16(11):40CrossRef Shakur H, Elbourne D, Gülmezoglu M, Alfirevic Z, Ronsmans C, Allen E, Roberts I (2010) The WOMAN Trial (World Maternal Antifibrinolytic Trial): tranexamic acid for the treatment of postpartum haemorrhage: an international randomised, double blind placebo controlled trial. Trials 16(11):40CrossRef
9.
Zurück zum Zitat Peitsidis P, Kadir RA (2011) Antifibrinolytic therapy with tranexamic acid in pregnancy and postpartum. Expert Opin Pharmacother 12(4):503–516PubMedCrossRef Peitsidis P, Kadir RA (2011) Antifibrinolytic therapy with tranexamic acid in pregnancy and postpartum. Expert Opin Pharmacother 12(4):503–516PubMedCrossRef
10.
Zurück zum Zitat Gleeson NC, Buggy F, Sheppard BL, Bonnar J (1994) The effect of tranexamic acid on measured menstrual loss and endometrial fibrinolytic enzymes in dysfunctional uterine bleeding. Acta Obstet Gynecol Scand 73(3):274–277PubMedCrossRef Gleeson NC, Buggy F, Sheppard BL, Bonnar J (1994) The effect of tranexamic acid on measured menstrual loss and endometrial fibrinolytic enzymes in dysfunctional uterine bleeding. Acta Obstet Gynecol Scand 73(3):274–277PubMedCrossRef
11.
Zurück zum Zitat Rath W, Hackethal A, Bohlmann MK (2012) Second-line treatment of postpartum haemorrhage. Arch Gynecol Obstet 286(3):549–561PubMedCrossRef Rath W, Hackethal A, Bohlmann MK (2012) Second-line treatment of postpartum haemorrhage. Arch Gynecol Obstet 286(3):549–561PubMedCrossRef
12.
Zurück zum Zitat Gai MY, Wu LF, Su QF, Tatsumoto K (2004) Clinical observation of blood loss reduced by tranexamic acid during and after caesarian section: a multi-center, randomized trial. Eur J Obstet Gynecol Reprod Biol 112(2):154–157PubMedCrossRef Gai MY, Wu LF, Su QF, Tatsumoto K (2004) Clinical observation of blood loss reduced by tranexamic acid during and after caesarian section: a multi-center, randomized trial. Eur J Obstet Gynecol Reprod Biol 112(2):154–157PubMedCrossRef
13.
Zurück zum Zitat Cook L, Roberts I, WOMAN Trial Collaborators (2010) Post-partum haemorrhage and the WOMAN trial. Int J Epidemiol 39(4):949–950PubMedCrossRef Cook L, Roberts I, WOMAN Trial Collaborators (2010) Post-partum haemorrhage and the WOMAN trial. Int J Epidemiol 39(4):949–950PubMedCrossRef
14.
Zurück zum Zitat Stafford I, Dildy GA, Clark SL, Belfort MA (2008) Visually estimated and calculated blood loss in vaginal and caesarean delivery. Am J Obstet Gynecol 199(5):519PubMedCrossRef Stafford I, Dildy GA, Clark SL, Belfort MA (2008) Visually estimated and calculated blood loss in vaginal and caesarean delivery. Am J Obstet Gynecol 199(5):519PubMedCrossRef
15.
Zurück zum Zitat Gohel M, Patel P, Gupta A, Desai P (2007) Efficacy of tranexamic acid in decreasing blood loss during and after caesarean section: a randomized case controlled prospective study. J Obstet Gynecol India 57:227–230 Gohel M, Patel P, Gupta A, Desai P (2007) Efficacy of tranexamic acid in decreasing blood loss during and after caesarean section: a randomized case controlled prospective study. J Obstet Gynecol India 57:227–230
16.
Zurück zum Zitat Gherman RB, Goodwin TM, Leung B, Byrne JD, Montoro M (1998) Incidence, clinical characteristics, and timing of objectively diagnosed venous thromboembolism during pregnancy. Prim Care Update Ob Gyns 5(4):155–156PubMedCrossRef Gherman RB, Goodwin TM, Leung B, Byrne JD, Montoro M (1998) Incidence, clinical characteristics, and timing of objectively diagnosed venous thromboembolism during pregnancy. Prim Care Update Ob Gyns 5(4):155–156PubMedCrossRef
17.
Zurück zum Zitat Toglia MR, Weg JG (1996) Venous thromboembolism during pregnancy. N Engl J Med 335(2):108–114PubMedCrossRef Toglia MR, Weg JG (1996) Venous thromboembolism during pregnancy. N Engl J Med 335(2):108–114PubMedCrossRef
18.
Zurück zum Zitat Shakur H, Roberts I et al (2010) Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 376(9734):23–32PubMedCrossRef Shakur H, Roberts I et al (2010) Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 376(9734):23–32PubMedCrossRef
19.
Zurück zum Zitat Caglar GS, Tasci Y, Kayikcioglu F, Haberal A (2008) Intravenous tranexamic acid use in myomectomy: a prospective randomized double-blind placebo controlled study. Eur J Obstet Gynecol Reprod Biol 137(2):227–231PubMedCrossRef Caglar GS, Tasci Y, Kayikcioglu F, Haberal A (2008) Intravenous tranexamic acid use in myomectomy: a prospective randomized double-blind placebo controlled study. Eur J Obstet Gynecol Reprod Biol 137(2):227–231PubMedCrossRef
20.
Zurück zum Zitat Sundström A, Seaman H, Kieler H, Alfredsson L (2009) The risk of venous thromboembolism associated with the use of tranexamic acid and other drugs used to treat menorrhagia: a case-control study using the General Practice Research Database. BJOG 116(1):91–97PubMedCrossRef Sundström A, Seaman H, Kieler H, Alfredsson L (2009) The risk of venous thromboembolism associated with the use of tranexamic acid and other drugs used to treat menorrhagia: a case-control study using the General Practice Research Database. BJOG 116(1):91–97PubMedCrossRef
21.
Zurück zum Zitat Taparia M, Cordingley FT, Leahy MF (2002) Pulmonary embolism associated with tranexamic acid in severe acquired haemophilia. Eur J Haematol 68(5):307–309PubMedCrossRef Taparia M, Cordingley FT, Leahy MF (2002) Pulmonary embolism associated with tranexamic acid in severe acquired haemophilia. Eur J Haematol 68(5):307–309PubMedCrossRef
22.
Zurück zum Zitat Imbesi S, Nettis E, Minciullo PL, Di Leo E, Saija A, Vacca A, Gangemi S (2010) Hypersensitivity to tranexamic acid: a wide spectrum of adverse reactions. Pharm World Sci 32(4):416–419PubMedCrossRef Imbesi S, Nettis E, Minciullo PL, Di Leo E, Saija A, Vacca A, Gangemi S (2010) Hypersensitivity to tranexamic acid: a wide spectrum of adverse reactions. Pharm World Sci 32(4):416–419PubMedCrossRef
23.
Zurück zum Zitat Schulz KF, Altman DG, Moher D (2010) CONSORT Group CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials BMJ 340:332 Schulz KF, Altman DG, Moher D (2010) CONSORT Group CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials BMJ 340:332
24.
Zurück zum Zitat Molenaar IQ, Warnaar N, Groen H, Tenvergert EM, Slooff MJ, Porte RJ (2007) Efficacy and safety of antifibrinolytic drugs in liver transplantation: a systematic review and meta-analysis. Am J Transplant 7(1):185–194PubMedCrossRef Molenaar IQ, Warnaar N, Groen H, Tenvergert EM, Slooff MJ, Porte RJ (2007) Efficacy and safety of antifibrinolytic drugs in liver transplantation: a systematic review and meta-analysis. Am J Transplant 7(1):185–194PubMedCrossRef
Metadaten
Titel
Tranexamic acid for cesarean section: a double-blind, placebo-controlled, randomized clinical trial
verfasst von
Mehmet B. Sentürk
Yusuf Cakmak
Gazi Yildiz
Pınar Yildiz
Publikationsdatum
01.04.2013
Verlag
Springer-Verlag
Erschienen in
Archives of Gynecology and Obstetrics / Ausgabe 4/2013
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-012-2624-8

Weitere Artikel der Ausgabe 4/2013

Archives of Gynecology and Obstetrics 4/2013 Zur Ausgabe

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

Blutdrucksenkung könnte Uterusmyome verhindern

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.